Business Context and Reporting Period
Company: SANUWAVE Health, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: An emerging global medical technology company focused on noninvasive, biological response activating devices (PACE technology) for regenerative medicine. The company is developing products for wound healing, orthopedic/spine, plastic/cosmetic, and cardiac conditions. Following the sale of its veterinary division in 2009, the company has no FDA-approved products currently in commercialization in the United States.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2010 | Six Months Ended June 30, 2009 |
|---|---|---|
| Revenues | $260,328 | $404,047 |
| Gross Profit | $171,748 (66% margin) | $305,384 (76% margin) |
| Operating Loss | $(5,439,950) | $(3,477,292) |
| Net Loss (Continuing Ops) | $(5,721,905) | $(3,824,041) |
| Net Loss (Total) | $(5,721,905) | $(750,462) |
| Cash and Equivalents (End of Period) | $277,258 | $3,139,068 |
| Total Debt (Notes Payable & Promissory) | $10,848,106 | $8,887,981 |
| Accumulated Deficit | $(44,382,186) | $(38,660,281) |
Note: 2009 Net Loss includes a gain of $2,492,273 from the sale of the veterinary division (discontinued operations).
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased 36% year-over-year to $260,328, primarily due to declining sales of the legacy Evotron device in Europe following the elimination of the European sales staff.
- Increased Operating Expenses:
- R&D: Increased 22% to $1,981,625, driven by the ongoing clinical trial for dermaPACE (diabetic foot ulcers).
- G&A: Increased 63% to $3,096,760. A significant portion ($937,700) was non-cash stock-based compensation. Excluding stock comp, G&A increased 32% due to bonus expenses.
- Depreciation: Increased 107% to $533,313, largely due to the reclassification of Ossatron assets from discontinued to continuing operations, restarting depreciation.
- Liquidity Deterioration: Cash and cash equivalents dropped by $1.51 million to $277,258. Net cash used by operating activities was $3.01 million.
- Debt Issuance: The company issued seven promissory notes totaling $1.5 million during the six-month period to fund operations.
Guidance, Outlook, and Risks
- Going Concern: The filing explicitly states substantial doubt about the company's ability to continue as a going concern due to recurring operating losses and an accumulated deficit of $44.4 million. The company is economically dependent on future financing.
- Product Pipeline:
- dermaPACE: Enrollment for the diabetic foot ulcer clinical trial is complete (206 patients). Top-line results expected in Q4 2010; FDA PMA filing expected Q1 2011.
- orthoPACE: Launched in Europe in June 2010 with CE Mark approval. First shipments occurred in July 2010.
- Financing Needs: Management anticipates operating losses will continue for several years. Additional capital is required for clinical trials and commercialization. Subsequent to quarter-end, a $500,000 convertible promissory note was issued on July 13, 2010.
- Risks: Risks include failure to complete clinical trials, inability to obtain regulatory approval, inability to secure additional financing, and limitations on the use of Net Operating Loss (NOL) carryforwards due to potential ownership changes.
Investor Verification Checklist
- Cash Runway: Verify current cash balance against monthly burn rate given the $277k cash position and $3M operating cash burn in six months.
- Debt Covenants & Maturities: Review terms of the $1.5M in promissory notes (some with penalty interest rates of 10% due to missed payments) and $9.3M in related party notes (15% interest, convertible).
- Clinical Trial Status: Confirm the timeline for the dermaPACE trial results and FDA PMA filing, as these are critical for future revenue generation.
- Stock-Based Compensation: Assess the impact of the $937k non-cash stock compensation expense on future dilution and cash flow projections.
- Legal Proceedings: Review the status of the breach of contract lawsuit involving HealthTronics and the Company, where the plaintiff seeks over $3 million.